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Abstract
Background
The intermittent preventive treatment in infants (IPTi) trial that took place in Papua New
Guinea showed an overall reduction of 29% of the risk of malaria when delivering single-
dose sulfadoxine-pyrimethamine (SP) associated to 3 days of amodiaquine (AQ) every
three months to children during the first year of life. The aim of the present study was to
assess if the last two doses of AQ were truly administered as prescribed by the parents at
home based on drug level measurement and PK modelling, which is a good proxy of medi-
cation adherence. It provides also important information to discuss the efficacy of the inter-
vention and on feasibility of self-administered preventive malaria treatment.
Methods and findings
During the three-arm randomized double-blinded IPTi trial, each child was prescribed one
dose of SP (day 0) and 3 doses of either AQ or artesunate (AS) at day 0, 1 & 2 adjusted to
weight or placebo. Treatments were given at 3, 6, 9 and 12 months of age. The first day of
treatment was delivered by nursing staff (initiation under directly observed treatment (DOT))
and the two last doses of AQ or AS by parents at home without supervision. For this cross-
sectional study, 206 consecutive children already involved in the IPTi trial were enrolled
over a 2-month period. At the time of the survey, allocation of the children to one of the three
arms was not known. Blood samples for drug level measurement were collected from finger
pricks one day after the planned last third dose intake. Only children allocated to the SP-AQ
arm were included in the present analysis. Indeed, the half-life of AS is too short to assess if
drugs were given on not. Because of the short half-life of AQ, desethyl-AQ (metabolite of
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AQ (DAQ)) measurements were used to investigate AQ medication adherence. Two PK
(PK) models from previously published studies in paediatric populations were applied to the
dataset using non-linear mixed effect modelling (NONMEM) to estimate the number of
doses really given by the parents. The study nurse reported the administration time for the
first AQ dose while it was estimated by the parents for the remaining two doses. Out of 206
children, 64 were in the SP-AQ arm. The adjusted dosing history for each individual was
identified as the one with the lowest difference between observed and individual predicted
concentrations estimated by the two PK models for all the possible adherence schemes.
The median (range) blood concentration AQ in AQ arm was 9.3 ng/mL (0–1427.8 ng/mL),
(Quartiles 1–3: 2.4 ng/mL -22.2 ng/mL). The median (range) for DAQ was 162.0 ng/mL (0–
712 ng/mL), (Quartiles 1–3: 80.4 ng/mL-267.7 ng/mL). Under the assumption of full adher-
ence for all participants, a marked underprediction of concentrations was observed using
both PK models. Our results suggest that only 39–50% of children received the three sched-
uled doses of AQ as prescribed, 33–37% two doses and 17–24% received only the first
dose administered by the study nurse. Both models were highly congruent to classify adher-
ence patterns.
Conclusions
Considering the IPTi intervention, our results seem to indicate that medication adherence is
low in the ideal trial research setting and is likely to be even lower if given in day-to-day prac-
tice, questioning the real impact that this intervention might have. More generally, the esti-
mation of the number of doses truly administered, a proxy measure of adherence and an
assessment of the feasibility of the mode of administration, should be more thoroughly stud-
ied when discussing the efficacy of the interventions in trials investigating self-administered
malaria preventive treatments.
Introduction
In Papua New Guinea (PNG), malaria transmission is high and the disease is responsible for
several thousands of deaths each year. The number of estimated cases in 2013 was between
800’000 and 2’000’000[1]. The major plasmodium species present in PNG are Plasmodium fal-
ciparum and Plasmodium vivax.
Intermittent preventive treatment in infants (IPTi) aims to reduce malaria risk by deliver-
ing several antimalarial drugs, three or four times, coinciding with immunization planned by
the Expended Program on Immunization (EPI) to children younger than 1 year[1–3], particu-
larly in regions where malaria transmission is moderate to high. Most of the drugs proposed
for this intervention have a long half-life, such as sulfadoxine-pyrimethamine (SP)[1]. The
principal aim of the IPTi trial that took place in Papua New Guinea was to investigate the pre-
ventive efficacy and the overall risk reduction against falciparum and vivax malaria of deliver-
ing four courses of antimalarial drugs to children during the first year of life. This three-arm
study, completed in 2010, showed an overall reduction of 29% in malaria risk using SP associ-
ated with amodiaquine (AQ) compared to placebo[4] and no significant effect of SP associated
to with artesunate (AS) compared to placebo.
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As the parents at home directly administer the second and third treatment doses without
supervision, overall the number of doses truly administered remains largely uncertain, which
might have a direct impact on the efficacy of the intervention. From a perspective of imple-
menting IPTi, as with any therapy with self-administered treatment, knowing the adherence
level is a key element. There are several reasons why infants might not receive the correct
amount of drugs: nurses not giving the right dosage or crushing the pill, which might induce
some loss of the active ingredient, children vomiting the drugs or the parents not administer-
ing drugs at home. The latter reason might be especially common in the case of IPTi, as it is a
preventive intervention and parents might find it less useful or might prefer keeping the drugs
for later use in case of malaria-like symptoms onset. In a qualitative study performed in chil-
dren of the present IPTI trial, about 15% of the mothers mentioned not having given the drugs
according to instructions[5]. In another qualitative study realised in five African countries by
Gysels et al.[5], they reported that it was common for mothers to forget giving the tablets or
keep them for later use.
Medication adherence is defined as the process by which patients take their medications as
prescribed by their healthcare providers[6]. Medication adherence is composed of three core
components: initiation, implementation (dosing and daily timing) and discontinuation. Time
between first and last dose is defined as “persistence”. Assessment of medication adherence
uses direct and indirect methods[7]. Indirect methods (e.g. self-report questionnaires) tend to
overestimate real medication adherence. Direct methods, whenever available, such as drug
blood-level monitoring, represent more objective assessments. However, concentration mea-
surements do not reflect long-term adherence to the treatment and important inter-individual
(e.g. genetic, age, body weight, concomitant drugs, foods, disease) and intra-individual varia-
tions (e.g. random changes in concentrations from one visit to the other) in drug levels occur,
which make the measurement of adherence more complex. We suggest to use PK (PK) model-
ling to estimate the number of doses truly taken according to blood drug concentrations at a
defined time point and taking into consideration other factors related to the patient (weight,
age. . .).This requires expertise in drug modelling and availability of reliable PK models. To
our knowledge, PK has never been used to test adherence to malaria preventive treatments.
The aim of the present study was to assess if the last two doses of AQ were truly adminis-
tered as prescribed by the parents at home based on drug level measurement and PK model-
ling, which is a good proxy of medication adherence and an assessment of the feasibility of
self-administred malaria preventive treatments. It provides also important information to dis-
cuss the efficacy of the intervention. It was performed in a random sample of 206 study partici-
pants included in the randomized controlled trial performed in Papua New Guinea.
Methods
The IPTi randomized controlled trial was conducted in PNG in the Mugil area of the Sumkar
District, Madang Province, between June 2006 and May 2010 and included 1125 children.
Each study participant received four courses of treatment at 3, 6, 9 and 12 months. Each course
consisted of three days of treatment and each time, nursing staff delivered SP (single dose) and
the first dose of AQ or AS (day 0, D0) by initiation under directly observed treatment (DOT)
and parents at home without supervision the others doses of AQ or AS (day 1 and 2). The tab-
lets were given with sweet syrup after being crushed by the nurse or parents. The first drug
dose (D0) was given a second time if the child vomited within 30 minutes. A community
reporter living in the village was in charge of visiting the children to check that no adverse
events occurred. He/she had no responsibility for giving drugs or supervising drug intake. All
details concerning the trial and efficacy results have been published elsewhere[5]. The study
Adherence to IPTi: A pharmacological study
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was carried out in accordance with Good Clinical Practice (ICH GCP E6) guidelines and exter-
nally monitored by two independent monitors and the Data Safety Monitoring Board. The
study (main protocol and present amendment) was approved by the PNG Medical Research
Advisory Committee (MRAC number 05.20). The trial was registered on http://www.
clinicaltrials.gov (number NCT00285662) and formed part of the IPTi Consortium (http://
www.ipti-malaria.org). In concordance with MRAC regulations, written informed consent
was obtained from the parents both for the main IPTi study and the present work.
For the present cross-sectional study, 206 consecutive children already part of the IPTi trial,
were enrolled over an approximate 2-month period. At the time of sampling, allocation groups
in the IPTi trial were unknown. Indeed, patients were assigned blindly into one of the three
trial arms (SP-AQ, SP-AS and placebo), so we enrolled a large number of children aiming to
have approximately 60 patients in each arm.
Nurses of the study team visited each of the 206 study participants at home one day (D3)
after the theoretical last-dose taken (D2). To avoid biasing the results of the study, parents
were not informed in advance of the visit. Blood samples for drug level measurement were col-
lected from finger pricks. The course of the study is detailed in Fig 1. An experienced study
nurse also collected at home parents’ estimated time of drug administration on day 1 and day
2 using a scale that divides day-time into 2-hour slices. Parents specifically consented to this
additional blood collection, not included in the main trial.
The blood samples of the 206 participants were used to measure the levels of IPTi drugs
(SP, AS and AQ + AQ-metabolites). Drug level measurements were conducted at the labora-
tory of the Division of clinical pharmacology of the University hospital of Lausanne, Switzer-
land, using a chromatography-tandem mass spectrometry method (LC-MS/MS) (Hodel-EM
et al 2009).
Children included in the PK analysis are those whose parents reported having given drugs
and with drug levels available. Each study participant was at a different stage of the study and
thus received the treatment course at 3, 6, 9 or 12 months. We performed the analysis on
patients in the AQ arm only. More specifically, we used desethyl-amodiaquine (metabolite of
AQ (DAQ)) measurements to if drugs were truly administered by parents as AS and AQ con-
centrations are low or undetectable one day after drug administration because of their short
half-lives (20–45 minutes and 4 hours in adults, respectively[8, 9]. This approach provides a
good proxy for medication adherence and the feasibility of self-administration of malaria pre-
ventive treatments in infants. For clarity, we will refer to the term “medication adherence” also
we are fully aware that it reflects only how many of the two last doses were really given by the
Fig 1. Diagram of the course of the study.
https://doi.org/10.1371/journal.pone.0210789.g001
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parents in the specific frame of the trial. It the perspective of the trial, it provides also valuable
information to discuss the efficacy of the IPTi intervention. SP was not investigated for adher-
ence as the study nurses administered the single dose. Children who were ill (criteria for
malaria were: fever and a positive rapid diagnostic test for malaria) up to one week before the
preventive treatment was due did not receive study drugs but received curative treatment with
lumefantrine-arthemeter (Coartem) and therefore were excluded from the study.
Non-linear mixed effect modelling (NONMEM, v7.3.0, ICON development Solutions, Elli-
cott City, MD, USA)) was employed to predict individual DAQ concentration (NONMEM
option MAXVAL = 0) [10]. This program offers the opportunity to characterize concentra-
tion-time profiles of drugs by estimating individual and population PK parameters, assessing
their variability and quantifying the impact of subjects’ factors on the P parameters. Since dos-
ing history was unknown and evaluated in the present study, we decided to apply previously
published models to our data instead of conducting a population PK analysis. A literature
research was performed with the aim of identifying PK models of AQ and DAQ disposition in
a paediatric population similar to the investigated one. We retrieved the mean PK parameters
with their variability and applied such models to our dataset to predict DAQ concentration
under the assumption of full (three doses, i.e. planned dosing history) or partial (only the dose
on day 0, doses on days 0 and 1, or doses on days 0 and 2) medication adherence. We calcu-
lated individual residuals (IRES) as the difference between predicted (Cpred) and (Cobs)
observed concentrations in each of the four adherence schemes and identified the true dosing
history for each child as the one associated with the lowest IRES value among the four possible
adherence patterns. Children were thus categorized into groups according to the identified
dosing history: subjects receiving a dose on day 0 (defined as configuration of adherence D_1,
i.e. only the first dose was taken), on days 0 and 1 (D_12) on days 0 and 2 (D_13), and those
who completed the treatment (D_123). We estimated bias and precision of the model assum-
ing theoretical full adherence and the model-corrected dosage history according to IRES values
by mean prediction error (MPE ¼
P
Cpred   Cobs
N , where Cpred and Cobs as previously defined
and N the number of observations) with the associated CI95%, and root mean squared error
(RMSE =
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiP
ðCpred   CobsÞ
2
N
q
) [11]. R v3.2.3 (R Development Core Team, http://www.r-project.
org/) was used for statistical analyses and figures generation.
Results
Literature search
A Pubmed search allowed us to identify two previously published studies in the paediatric pop-
ulation. Hietala et al. [8] analysed data collected from children aged from 3 months to 12 years
from Tanzania and Papua New Guinea, while Stepniewska et al. [12] analysed a population of
children from 6 months to 5 years in Burkina Faso. In both studies, DAQ PKs was best
described by a two-compartment model with first-order absorption and elimination. Body
weight was found to influence DAQ disposition. An additional association between age and
DAQ clearance was reported by Hietala et al.[8]. As described in Table 1, both models provide
similar PK parameters. For both models, a very long DAQ terminal half-life (from 3 to 8 days
in Hietala et al. [8] and from 7 to 12 days in Stepniewska et al. [12]) was estimated.
Pharmacokinetic analyses
Out of 206 children, 68 belonged to the SP-AQ arm. One was removed because parents said
they did not give the third dose and three because blood was not collected, thus 64 children
Adherence to IPTi: A pharmacological study
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fulfilled the inclusion criteria (Fig 2). Age, weight and gender characteristics of the study par-
ticipants are described in Table 2 and compared to those of patients in both studies used as
models for the PK analysis.
The median (range) AQ blood concentration in the AQ arm was 9.3 ng/mL (0–1427.8 ng/
mL), (Quartiles 1–3: 2.4 ng/mL -22.2 ng/mL). The median (range) for DAQ was 162.0 ng/mL
(0–712 ng/mL), (Quartiles 1–3: 80.4 ng/mL-267.7 ng/mL).
In comparison, the median (range) AQ blood concentration in the placebo arm was 0 ng/
mL (0–137.0 ng/mL), (Quartiles 1–3: 0 ng/mL -0.2 ng/mL). The median (range) for DAQ was
Table 1. Estimated PK parameters for DAQ, for both models.
Models
Parameters Hietala(10) Stepniewska(12)
Estimate (RSE%) Estimate (SE)
Ka (h-1) 0.13 (31) 0.13 (fixed)
CL/F (L Kg-1 h-1) 0.67 (10) 0.610 (0.038)
Q (L Kg-1 h-1) 1.3 (23) 0.680 (0.306)
Vcentral/F (L Kg
-1) 12.8 (44) 35.4 (11.5)
Vperipheral/F (L Kg
-1) 62.4 (9) 87.9 (17.1)
T ½ (days) 4.9 [3.3–8.0]1 9.0 [7.3–11.6]1
σ 25 fixed 0.457
Ka: absorption rate constant; CL/F: total clearance; Q: intercompartmental clearance; Vcentral/F: volume of the central
compartment; Vperipheral/F: volume of the peripheral compartment; F: fraction of drug absorbed; σ: residual additive
error on the loge scale
1range of predicted values
https://doi.org/10.1371/journal.pone.0210789.t001
Fig 2. Selection of the patients eligible for the PK analysis.
https://doi.org/10.1371/journal.pone.0210789.g002
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0.7 ng/mL (0–202.1 ng/mL), (Quartiles 1–3: 0 ng/mL-6.3 ng/mL). Overall, 16/65 patients had
detectable concentrations of AQ and 34/65 of DAQ.
Assuming full adherence, we observed a marked under prediction of concentrations using
both the Hietala and the Stepniewska models. Fig 3 illustrates the observed vs. individual Hie-
tala and Stepniewska model-predicted concentrations for the theoretical and adjusted dosing
datasets.
The results suggest that 11 children (17%) are in adherence configuration D_1, 8 (13%) in
D_13, 13 (20%) in D_12 and 32 (50%) received full treatment according to the Hietala model.
Applying the Stepniewska model provided similar results, with 15 children (24%) in configura-
tion D_1, 13 (20%) in D_13, 11 (17%) in D_12 and 25 (39%) received all three doses. The two
models agreed on the adherence schemes for 80% of the children. Discrepant results were
observed in thirteen children. For seven of them, the adherence schemes were D_123 vs.
D_13, for four of them, D_12 vs. D_1, and for two of them, D_13 vs. D_12, comparing the Hie-
tala vs. Stepniewska models, respectively.
The bias (95% confidence interval CI95%) was 20% (CI95% 4–38%) with a precision of 79%
for the Hietala model and was 82% (CI95% 40–138%) with a precision of 236% using the Step-
niewska model. Under the assumption of model-identified adherence, the initial bias and pre-
cision of the Hietala model decreased to -4% (CI95% -14-6%) with a precision of 50% and to
2% (CI95% -14-20%) with a precision of 97% using the Stepniewska model and was thus not
significantly different from zero. The observed vs. individual predicted concentrations under
the assumption of each adherence configuration for both models are shown in S1 and S2 Figs.
Tables 3 and 4 show the four adherence patterns, stratified by age, according to both
models.
Discussion
This study suggests that a majority of children did not receive the full IPTi treatment within
the frame of the randomized trial, which could substantially decrease the optimal efficacy of
the intervention. Our results indeed showed that only 39 to 50% of children, depending on the
PK model used, received the three scheduled doses of AQ, while 33 to 37% received two doses
and 17 to 24% received only the first dose, administered by the study nurse.
In the present study, drug concentration measurements was used as a proxy of medication
adherence in the frame of the trial. Even though it is not a direct measure of adherence, we
believe that this approach provides important information related to adherence in the context
of a trial that might also useful, by extension, to estimate what would happen if the interven-
tion would be implemented in real life. It informs also on the feasibility of the self-administra-
tion approach for preventive malaria treatments in infants. Finally, this information is also of
prime importance to discuss the overall efficacy of the intervention.
Table 2. Characteristics of the patients in the present study compared to both models used.
Present study
n = 64
Hietala[10]
n = 329
Stepniewska[12]
n = 70
Age (years or months)
(mean[range])
6 months [2–13] 2.5 years [0.3–10] 27.5 months [7–59]
Weight (kg) 7 [4–10] 13.151 [8–27] 12 [6–31]
Gender ratio (male/female) 43/21 166/163 36/34
1n = 117, weight was not specified for all patients
https://doi.org/10.1371/journal.pone.0210789.t002
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Results of the modelling showed that imputing a partial adherence instead of considering a
full dosing schedule explained the discrepancy between measured and expected drug concen-
trations. The major bias observed while assuming full adherence to prescribed dosing became
not-significantly different from 0 using the adjusted dosing history. This supports the
Fig 3. Observed versus individual predicted DAQ concentrations under the assumption of full and model-identified adherence.
https://doi.org/10.1371/journal.pone.0210789.g003
Adherence to IPTi: A pharmacological study
PLOS ONE | https://doi.org/10.1371/journal.pone.0210789 February 6, 2019 8 / 13
adequacy of the actual dosing history including several scenarios of missed doses. Moreover,
although some differences in PK estimates were present between both models, they were
highly congruent at classifying adherence patterns in children, which reinforces the validity
the results. We can therefore be confident that this approach provides a reliable estimation of
short-term AQ medication adherence.
We observed different medication adherence patterns. Adherence to the first dose was
100%, what is reinsuring about the study procedure, as it was DOT-delivered by the study
nurse. Only half of the children showed adherence to the subsequent doses, while the others
had only partial medication adherence. Either they did not take the last dose, and therefore dis-
continued IPTi too early, or they did not take the middle dose. Early discontinuation was
more frequent (37–41%) than non-ingestion of the middle dose (13–20%). It is interesting to
note that adherence to the full IPTI treatment in this study was very close to the levels found in
the literature for real life adherence to long-term medication for chronic diseases (around
50%), a totally different context[13].
These results show that, even in the frame of a well-controlled clinical trial, adherence is far
from optimal. Furthermore,Even if parents at home were responsible to administer the last
two doses, a community reporter was responsible for visiting families each treatment day,
checking for serious adverse events and collecting empty drug bags (thus serving indirectly as
a reminder for drug intake). This type of check procedure is possible only in the frame of a
Table 3. Results by age according to Hietala model.
Adjusted dosing dataset
Course of treatment Dose 1 Doses 1 and 3 Doses 1 and 2 Doses 1, 2 and 3 Nb of patients
1 at 3 months 4 (17%) 3 (13%) 3 (13%) 13 (57%) 23
(Nb of children (% by age))
2 at 6 months 2 (13%) 3 (19%) 3 (19%) 8 (50%) 16
(Nb of children (% by age))
3 at 9 months 3 (23%) 1 (8%) 2 (15%) 7 (54%) 13
(Nb of children (% by age))
4 at 12 months 2 (17%) 1 (8%) 5 (42%) 4 (33%) 12
(Nb of children (% by age))
Total 11 (17%) 8 (13%) 13 (20%) 32 (50%) 64
(Nb of children (% of the total))
https://doi.org/10.1371/journal.pone.0210789.t003
Table 4. Results by age according to Stepniewska model. Nb children (% by age).
Adjusted dosing dataset
Course of treatment Dose 1 Doses 1 and 3 Doses 1 and 2 Doses 1, 2 and 3 Nb of patients
1 at 3 months 4 (17%) 5 (22%) 4 (17%) 10 (44%) 23
(Nb of children (% by age))
2 at 6 months 3 (19%) 5 (31%) 2 (13%) 6 (37%) 16
(Nb of children (% by age))
3 at 9 months 4 (31%) 1 (8%) 2 (15%) 6 (46%) 13
(Nb of children (% by age))
4 at 12 months 4 (33%) 2 (17%) 3 (25%) 3 (25%) 12
(Nb of children (% by age))
Total 15 (24%) 13 (20%) 11 (17%) 25 (39%) 64
(Nb of children (% of the total))
https://doi.org/10.1371/journal.pone.0210789.t004
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trial, and certainly not in routine care. Although impossible to make clear assumptions one
way or another, we may still wonder what the real efficacy of SP-AQ would have been if the
adherence had been 100% instead of 50%.
The results of this study also question the potential impact of a preventive intervention with
self-administered treatment such as IPTi if implemented in a real-life context. Indeed, the
observed adherence of 37% to 50% for the full treatment course is certainly the highest that
one could expect in a less controlled context. Furthermore, for an intervention such as IPTi,
most of the protection is due to the prophylactic effect long-acting drugs as mentioned in the
main trial publication. [4] SP is therefore likely to be responsible for the most important part
of the observed protection, and the results of this study reinforces the hypothesis that the
added benefit of AQ is limited, also if it has also a relative long half-life (> 7days). In the trial,
adherence to SP was close to 100%, which is unachievable in daily practice, even if the dose is
given by a health professional. In an observational implementation-effectiveness study in Tan-
zania conducted by Armstrong Schellenberg et al., it was observed that only 47 to 76% children
received the first dose of SP in an area where IPTi is carried out. They also assumed that chil-
dren without health cards did not receive IPTi and approximately one third did not receive
IPTi at the same time as immunization as staff forgot to give the drug or it was out-of-stock
[10]. Thus, it is likely that, if IPTi is widely implemented in PNG, the overall reduction of
malaria risk would be much lower than the 29% observed.
On the other hand, one might argue that the overall risk reduction observed is under-esti-
mated due to the fact that many children take non-prescribed “over-the-counter” antimalarial
drugs, especially AQ. In the present study, even if the measures of AQ blood concentrations
revealed that half of the children in the placebo arm took “over-the-counter” AQ and almost
all SP (data not shown), the concentrations were much lower than in the SP-AQ arm. It is
likely therefore that SP and AQ “over-the-counter” medications had only a marginal effect on
the overall protection in this study population even more as resistance to these two drugs were
low at the time of the study.
The reasons for only 50% or less of the children receiving all three doses of IPTi may be
multiple. First, it could be related to the preventive nature of the intervention. Indeed, parents
may decide to keep the antimalarial drugs for later use, in case of illness rather than giving it to
their healthy child. Second, since AQ tastes very bitter, children might have vomited or spat
out the drugs. Third, and most probably, parents may just have forgotten to give the treatment,
especially as no immediate benefit of the treatment is expected. Lastly, almost half the children
aged 3-months received the three doses while only one third of those aged 12 months did.
These results seem to indicate that parents are more likely to give a preventive treatment to
younger children than to older ones. Overall, the results of the study point out that self-admin-
istration of malaria preventive treatments is probably a suboptimal approach.
More generally, our study showed that it is feasible and reliable to assess objectively malaria
treatment adherence using PK modelling, even in complex research settings. We are not aware
of other studies that use this approach to investigate malaria adherence in developing, at least
for preventive treatments. Few studies have compared drugs levels at the end of curative treat-
ment courses to make broad assumptions on adherence, but not to measure precisely the num-
ber of doses taken.[14, 15] Our study highlights also the important gap between self-reported
adherence (all parents reported having given the full treatment course) and an objective assess-
ment, which is of importance. Furthermore, for the present trial, a qualitative acceptability
study was conducted and concluded that the intervention was well suited to the local PNG cul-
ture.[5] This illustrates how difficult it is to make clear assumptions on the true adherence
trough other ways than objective drug level measurements and PK analysis. Thus, this study
provides a new insight on how to assess objectively the true adherence to short courses of
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malaria treatments. This can have important implications for researchers and policy makers,
who could integrate more often such approaches at the time of interpreting effect sizes of inter-
ventions and allow a better anticipation of the potential benefits that an intervention might
have. This could also apply to other research filed than malaria.
A first limitation is that a full PK model could not be built due to the scarcity of data and we
performed the analysis based on previously published models in children. These models were
derived from older children, mostly from Africa, and were not validated in younger children
in PNG. However, in order to control for an “effect model”, we tested both published models
and found very similar results, which reinforces the reliability of the results. Second, the rela-
tively small sample size of the study might not reflect the adherence of the entire cohort of
patients. On the other hand, even if some uncertainties may remain on the exact proportion of
patients with poor adherence, the objective of this study was more to provide estimations
rather than an exact figure. Furthermore, this is probably a conservative estimate of the adher-
ence, mainly because we cannot exclude that some parents may have administered the treat-
ment to their child at last minute because they heard that study staff were coming (even if our
visit was not announced). Lastly, some uncertainties exist about the exact time at which the
drugs were taken. However, the careful history taking performed by the nurses allowed a time
estimate of around 2 hours, which is sufficient for the purpose of this analysis, especially con-
sidering the long half-life of DAQ.
Conclusion
This study showed that less than half of the study participants in an IPTi randomized con-
trolled clinical trial took the full three-day course of antimalarial preventive medication. This
is very low considering that the first dose was directly administered by a study nurse and the
study was closely monitored. These results seem to indicate that medication adherence is low
in an ideal research setting and therefore might be even lower if implemented in day-to-day
practice, questioning the impact that this intervention might really have. It also reinforces the
hypothesis that AQ add little to the overall efficacy of the IPTi intervention, which relies
mostly on the long lasting effect of a single dose of SP. Finally, these results question the self-
administration approach for preventive malaria treatments in children. This is relevant infor-
mation, not only for the specific IPTi intervention, but also more generally for drug trials of
this kind. Indeed, researchers should consider using this approach when designing new studies
and estimating effect sizes of short malaria treatment courses.
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